Document is current

Article History

Received: 27 July 2022

Accepted: 17 August 2022

First Online: 16 September 2022

Funding

: Adelphi Values were commissioned by Novartis Pharma AG, Basel, Switzerland to conduct this study. Novartis also funded the Rapid Service Fee.

: C.C. contributed to the conception or design of the study, conducted physician interviews, contributed substantially to the data analysis and interpretation, was a major contributor in writing the manuscript, and provided final approval of the publication. C.C. is a former employee of Adelphi Values and was employed by Adelphi Values during the conduct of this study. S.W. contributed to the conception or design of the study, contributed substantially to the data analysis and interpretation, and provided critical review and final approval of the publication. S.W. is a former employee of Adelphi Values and was employed by Adelphi Values during the conduct of this study. R.W.H. contributed to the conception or design of the study, contributed substantially to the data analysis and interpretation, and provided final approval of the publication. A.B. contributed to the data analysis and interpretation and provided critical review and final approval of the publication. B.N. contributed to the conception or design of the study, contributed to the data analysis and interpretation, and provided critical review and final approval of the publication. W.H. contributed to the conception or design of the study, contributed to the data analysis and interpretation, and provided critical review and final approval of the publication. P.G. contributed to the conception or design of the study, contributed to the data analysis and interpretation, and provided critical review and final approval of the publication.

: This manuscript is based on work that was previously published as a conference abstract and presented as a poster at ACR Convergence 2021 [Wratten S., Cooper C., Flynn J., Griffiths N., Hall R., Abetz-Webb L., Bowman S., Hueber W., Ndife B., Goswami P. Patient and Physician Perspectives on EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): A Qualitative Interview Study [abstract]. <i>Arthritis Rheumatol.</i> 2021; 73 (suppl 10). . Accessed 8 August 2022].

: Rebecca Williams-Hall is an employee of Adelphi Values, a health outcomes agency commissioned by Novartis to conduct this research. At the time of the study, Carl Cooper and Samantha Wratten were also employed by Adelphi Values, but are currently employees of Evidera Ltd and IQVIA, respectively. Arthur Bookman is a Principal Investigator recruiting patients for Novartis-sponsored clinical trials. Briana Ndife, Wolfgang Hueber and Pushpendra Goswami are employed by Novartis.

: Ethical approval and oversight was provided by Salus Independent Review Board (IRB), a centralised IRB in the USA (physician protocol ID: NO9051A; patient protocol ID: NO9052A). All participants provided oral and written informed consent prior to the conduct of any research activities. Both studies were designed and conducted in accordance with best practice guidelines and the ethical principles laid down in the Declaration of Helsinki and its later amendments.

: The datasets generated during and/or analysed during the current study are not publicly available owing to participants consenting to data being published in aggregated form and full interview recordings/transcripts only being available to the project team responsible for conducting the research.